Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Curr Pharm Des. 2011;17(19):1890-910. doi: 10.2174/138161211796718233.
Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPA's proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diagnostic marker, predictive tool of survival or clinical response, and as a target for therapy and imaging. This review summarizes the possibilities of uPAR in clinical applications for cancer patients.
几十年来，尿激酶型纤溶酶原激活物（uPA）系统一直与恶性细胞的侵袭有关。尿激酶受体（uPAR）是该蛋白水解级联反应中的关键参与者之一，因为它将 uPA 的蛋白水解活性集中在细胞表面，并具有信号受体的功能。uPAR 在几乎所有人类癌症中都高度表达，这表明它可能具有作为诊断标志物、生存或临床反应的预测工具以及作为治疗和成像的靶点的临床应用。本文综述了 uPAR 在癌症患者临床应用中的可能性。
